The usefulness of 99mTc-tetrofosmin SPECT in monitoring the response to chemotherapy in lung cancer patients.

Angela Spanu, Francesco Ginesu, Pietro Pirina, Orazio Schillaci, Antonio Farris, Francesca Chessa, Giordano Madeddu, Antonio Falchi, Giuseppe Madeddu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We evaluated the usefulness of 99mTc-tetrofosmin (TF) scintigraphy in monitoring chemotherapy response in 31 inoperable lung cancer (LC) patients, 24 NSCLC and 7 SCLC. In all cases after 740 MBq 99mTc-TF i.v. injection both planar and SPECT images were acquired, before and after 3 cycles of chemotherapy; SPECT was analysed both qualitatively and semiquantitatively by calculating tumor/background ratio (T/B). Scintigraphic data were always related to CT findings, according to which patients were classified into 2 groups after therapy: responders (with >or=50% reduction in tumor size) and non-responders (with an increase or no change/no significant reduction in tumor size). Four patients were rechecked for the third time, during long-term follow-up. SPECT images, positive before therapy in all cases, were concordant with CT in assessing treatment response in 13/13 responders and in 18/18 non-responder patients, showing tumor reduction in the former and an increase or no change/no significant reduction in the latter. Planar imaging failed to give additional information but also led to disease down-staging in some cases. T/B ratio significantly decreased after therapy (1.67+/-0.39 vs. 3.02+/-0.87, p

Original languageEnglish
Pages (from-to)1701-1707
Number of pages7
JournalOncology Reports
Volume10
Issue number6
Publication statusPublished - Nov 2003

Fingerprint

Single-Photon Emission-Computed Tomography
Lung Neoplasms
Drug Therapy
Neoplasms
Group Psychotherapy
Radionuclide Imaging
Therapeutics
technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Spanu, A., Ginesu, F., Pirina, P., Schillaci, O., Farris, A., Chessa, F., ... Madeddu, G. (2003). The usefulness of 99mTc-tetrofosmin SPECT in monitoring the response to chemotherapy in lung cancer patients. Oncology Reports, 10(6), 1701-1707.

The usefulness of 99mTc-tetrofosmin SPECT in monitoring the response to chemotherapy in lung cancer patients. / Spanu, Angela; Ginesu, Francesco; Pirina, Pietro; Schillaci, Orazio; Farris, Antonio; Chessa, Francesca; Madeddu, Giordano; Falchi, Antonio; Madeddu, Giuseppe.

In: Oncology Reports, Vol. 10, No. 6, 11.2003, p. 1701-1707.

Research output: Contribution to journalArticle

Spanu, A, Ginesu, F, Pirina, P, Schillaci, O, Farris, A, Chessa, F, Madeddu, G, Falchi, A & Madeddu, G 2003, 'The usefulness of 99mTc-tetrofosmin SPECT in monitoring the response to chemotherapy in lung cancer patients.', Oncology Reports, vol. 10, no. 6, pp. 1701-1707.
Spanu A, Ginesu F, Pirina P, Schillaci O, Farris A, Chessa F et al. The usefulness of 99mTc-tetrofosmin SPECT in monitoring the response to chemotherapy in lung cancer patients. Oncology Reports. 2003 Nov;10(6):1701-1707.
Spanu, Angela ; Ginesu, Francesco ; Pirina, Pietro ; Schillaci, Orazio ; Farris, Antonio ; Chessa, Francesca ; Madeddu, Giordano ; Falchi, Antonio ; Madeddu, Giuseppe. / The usefulness of 99mTc-tetrofosmin SPECT in monitoring the response to chemotherapy in lung cancer patients. In: Oncology Reports. 2003 ; Vol. 10, No. 6. pp. 1701-1707.
@article{5ffb4cbbf02b4a7ca4c6ba25eae9c780,
title = "The usefulness of 99mTc-tetrofosmin SPECT in monitoring the response to chemotherapy in lung cancer patients.",
abstract = "We evaluated the usefulness of 99mTc-tetrofosmin (TF) scintigraphy in monitoring chemotherapy response in 31 inoperable lung cancer (LC) patients, 24 NSCLC and 7 SCLC. In all cases after 740 MBq 99mTc-TF i.v. injection both planar and SPECT images were acquired, before and after 3 cycles of chemotherapy; SPECT was analysed both qualitatively and semiquantitatively by calculating tumor/background ratio (T/B). Scintigraphic data were always related to CT findings, according to which patients were classified into 2 groups after therapy: responders (with >or=50{\%} reduction in tumor size) and non-responders (with an increase or no change/no significant reduction in tumor size). Four patients were rechecked for the third time, during long-term follow-up. SPECT images, positive before therapy in all cases, were concordant with CT in assessing treatment response in 13/13 responders and in 18/18 non-responder patients, showing tumor reduction in the former and an increase or no change/no significant reduction in the latter. Planar imaging failed to give additional information but also led to disease down-staging in some cases. T/B ratio significantly decreased after therapy (1.67+/-0.39 vs. 3.02+/-0.87, p",
author = "Angela Spanu and Francesco Ginesu and Pietro Pirina and Orazio Schillaci and Antonio Farris and Francesca Chessa and Giordano Madeddu and Antonio Falchi and Giuseppe Madeddu",
year = "2003",
month = "11",
language = "English",
volume = "10",
pages = "1701--1707",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - The usefulness of 99mTc-tetrofosmin SPECT in monitoring the response to chemotherapy in lung cancer patients.

AU - Spanu, Angela

AU - Ginesu, Francesco

AU - Pirina, Pietro

AU - Schillaci, Orazio

AU - Farris, Antonio

AU - Chessa, Francesca

AU - Madeddu, Giordano

AU - Falchi, Antonio

AU - Madeddu, Giuseppe

PY - 2003/11

Y1 - 2003/11

N2 - We evaluated the usefulness of 99mTc-tetrofosmin (TF) scintigraphy in monitoring chemotherapy response in 31 inoperable lung cancer (LC) patients, 24 NSCLC and 7 SCLC. In all cases after 740 MBq 99mTc-TF i.v. injection both planar and SPECT images were acquired, before and after 3 cycles of chemotherapy; SPECT was analysed both qualitatively and semiquantitatively by calculating tumor/background ratio (T/B). Scintigraphic data were always related to CT findings, according to which patients were classified into 2 groups after therapy: responders (with >or=50% reduction in tumor size) and non-responders (with an increase or no change/no significant reduction in tumor size). Four patients were rechecked for the third time, during long-term follow-up. SPECT images, positive before therapy in all cases, were concordant with CT in assessing treatment response in 13/13 responders and in 18/18 non-responder patients, showing tumor reduction in the former and an increase or no change/no significant reduction in the latter. Planar imaging failed to give additional information but also led to disease down-staging in some cases. T/B ratio significantly decreased after therapy (1.67+/-0.39 vs. 3.02+/-0.87, p

AB - We evaluated the usefulness of 99mTc-tetrofosmin (TF) scintigraphy in monitoring chemotherapy response in 31 inoperable lung cancer (LC) patients, 24 NSCLC and 7 SCLC. In all cases after 740 MBq 99mTc-TF i.v. injection both planar and SPECT images were acquired, before and after 3 cycles of chemotherapy; SPECT was analysed both qualitatively and semiquantitatively by calculating tumor/background ratio (T/B). Scintigraphic data were always related to CT findings, according to which patients were classified into 2 groups after therapy: responders (with >or=50% reduction in tumor size) and non-responders (with an increase or no change/no significant reduction in tumor size). Four patients were rechecked for the third time, during long-term follow-up. SPECT images, positive before therapy in all cases, were concordant with CT in assessing treatment response in 13/13 responders and in 18/18 non-responder patients, showing tumor reduction in the former and an increase or no change/no significant reduction in the latter. Planar imaging failed to give additional information but also led to disease down-staging in some cases. T/B ratio significantly decreased after therapy (1.67+/-0.39 vs. 3.02+/-0.87, p

UR - http://www.scopus.com/inward/record.url?scp=2642580244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642580244&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 1701

EP - 1707

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -